• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Luxenburg Kalfon Hana

    3/18/26 5:35:05 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MDWD alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Luxenburg Kalfon Hana

    (Last)(First)(Middle)
    C/O MEDIWOUND LTD.
    42 HAYARKON STREET

    (Street)
    YAVNE8122745

    (City)(State)(Zip)

    ISRAEL

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/18/2026
    3. Issuer Name and Ticker or Trading Symbol
    MediWound Ltd. [ MDWD ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Financial Officer
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Ordinary shares(1)4,085D
    Ordinary shares(2)3,000D
    Ordinary shares(3)3,200D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option (right to buy ordinary shares) (4)05/14/2033Ordinary shares39,000$11.9D
    Stock Option (right to buy ordinary shares) (5)02/26/2034Ordinary shares32,681$12.729D
    Stock Option (right to buy ordinary shares) (6)02/11/2035Ordinary shares24,000$18.54D
    Stock Option (right to buy ordinary shares) (7)03/04/2036Ordinary shares26,000$17.6D
    Explanation of Responses:
    1. The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
    2. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
    3. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
    4. The options reported in this row were granted to the Reporting Person on May 31, 2023 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
    5. The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
    6. The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
    7. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
    /s/ Yaron Meyer, attorney-in-fact03/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $MDWD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDWD

    DatePrice TargetRatingAnalyst
    6/2/2025$34.00Outperform
    Oppenheimer
    5/2/2025$25.00Buy
    Alliance Global Partners
    2/28/2025$39.00Buy
    Craig Hallum
    7/16/2024$25.00 → $30.00Buy
    Maxim Group
    12/22/2022$11.00Buy
    Maxim Group
    7/18/2022$7.00Outperform
    Oppenheimer
    8/17/2021$10.00 → $9.00Buy
    Aegis Capital
    8/11/2021$7.00 → $6.50Buy
    HC Wainwright & Co.
    More analyst ratings

    $MDWD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MediWound Files Annual Report on Form 20-F

    MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5, 2026 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the "SEC") on March 5, 2026. The annual report can be accessed on the SEC's website at http://www.sec.gov, as well as via the Company's investor relations website at http://ir.mediwound.com. The Company will provide a hard copy of its annual report on Form 20-F, including its audited financial statements, free of charge, to its shareholders upon request.

    3/5/26 4:30:00 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

    EscharEx® Phase III VALUE trial advancing as planned Expanded NexoBrid® manufacturing facility operational; regulatory approvals expected in 2026 $17 million revenue in 2025; $54 million in cash at year-end; 2026–2028 revenue guidance reaffirmed Conference Call Today, March 5, 2026, at 8:30 a.m. Eastern Time YAVNE, Israel, March 05, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2025. "We entered 2026 with two strategic growth drivers," said Ofer Gonen, Chief Executive Officer of MediWound. "O

    3/5/26 7:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    MediWound to Report Fourth Quarter and Full Year 2025 Financial Results

    MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 5, 2026. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide business highlights. Conference Call & Webcast Details Toll-Free:                1-8

    2/19/26 8:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on MediWound with a new price target

    Oppenheimer resumed coverage of MediWound with a rating of Outperform and set a new price target of $34.00

    6/2/25 8:53:24 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    Alliance Global Partners initiated coverage on MediWound with a new price target

    Alliance Global Partners initiated coverage of MediWound with a rating of Buy and set a new price target of $25.00

    5/2/25 8:15:09 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on MediWound with a new price target

    Craig Hallum initiated coverage of MediWound with a rating of Buy and set a new price target of $39.00

    2/28/25 7:39:12 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Klinger Ety

    3 - MediWound Ltd. (0001593984) (Issuer)

    3/18/26 5:33:55 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Fox David Morton

    3 - MediWound Ltd. (0001593984) (Issuer)

    3/18/26 5:31:49 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Luxenburg Kalfon Hana

    3 - MediWound Ltd. (0001593984) (Issuer)

    3/18/26 5:35:05 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

    Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-10) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 08/15/2024. Application Category: BLA, Application Number: 761192, Application Classification:

    8/16/24 4:36:54 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

    Submission status for MEDIWOUND, LTD's drug NEXOBRID (ORIG-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:

    12/30/22 4:38:06 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

    Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:

    12/29/22 1:11:07 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    SEC Filings

    View All

    SEC Form S-8 filed by MediWound Ltd.

    S-8 - MediWound Ltd. (0001593984) (Filer)

    3/5/26 4:24:11 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 20-F filed by MediWound Ltd.

    20-F - MediWound Ltd. (0001593984) (Filer)

    3/5/26 7:30:50 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by MediWound Ltd.

    6-K - MediWound Ltd. (0001593984) (Filer)

    3/5/26 7:05:14 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

    SC 13G/A - MediWound Ltd. (0001593984) (Subject)

    11/14/24 7:55:11 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

    SC 13G/A - MediWound Ltd. (0001593984) (Subject)

    10/23/24 2:57:43 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by MediWound Ltd.

    SC 13G - MediWound Ltd. (0001593984) (Subject)

    10/1/24 8:23:53 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    Leadership Updates

    Live Leadership Updates

    View All

    MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

    YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound. "We are delighted to welcome Shmulik, a distinguished industry executive, to our team. Dr. Hess joins MediWound during a crucial phase of expansion as we diligently implement our global strategy. Given Shmulik's outstanding track record in international o

    11/21/23 7:00:00 AM ET
    $ENLV
    $MDWD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

    YAVNE, Israel, and DENKENDORF, Germany, Nov. 08, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, and PolyMedics Innovations (PMI), an innovative biomaterials company specializing in effective wounds treatment, today announced an agreement for the promotion of NexoBrid® in Germany, Austria, Belgium, the Netherlands and Luxemburg. Feedback from key opinion leaders and customers indicates that NexoBrid, a non-surgical solution for eschar removal in burns, is a perfect complement to PMI's existing product line, including SUPRATHEL®, NovoSorb® BTM, and SUPRA SDRM®. Along wit

    11/8/23 7:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer

    YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound's Chief Financial Officer for the past four years. Mr. Gur-Lavie will remain with the Company through July 31, 2023 to ensure an orderly transition. With over 20 years of progressive leadership experience managing financial and accounting operations, Ms. Luxenburg joins MediWound wi

    3/16/23 7:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    Financials

    Live finance-specific insights

    View All

    MediWound to Report Fourth Quarter and Full Year 2025 Financial Results

    MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 5, 2026. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide business highlights. Conference Call & Webcast Details Toll-Free:                1-8

    2/19/26 8:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    MediWound to Report Third Quarter 2025 Financial Results

    MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd. (NASDAQ:MDWD) (the "Company"), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2025 on Thursday, November 20, 2025. Following the release, the Company's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Dial-in and call details are as follows: Conference Call & Webcast

    11/5/25 7:30:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Million, Up 43% from Prior Quarter Conference Call Today, August 14, 2025, at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. "We continue to execute acr

    8/14/25 7:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care